Panagiota-Angeliki Galliou

Ms. Panagiota-Angeliki Galliou

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
PGPanagiota-Angeliki Galliou
Panagiota-Angeliki Galliou
ANArgyri Niti
Argyri Niti
MPMaria Papaioannou
Maria Papaioannou
Georgios KoliakosGeorgios Koliakos
Georgios Koliakos
NPNikolaos Papanikolaou
Nikolaos Papanikolaou
Background/Objectives: Mesenchymal stem cells (MSCs) possess immunomodulatory properties, tumor-homing, and low immunogenicity, making them attractive for cell-based cancer therapies, but their role in colorectal cancer (CRC) remains controversial. The MSC1 phenotype, a pro-inflammatory, tumor-suppressive state induced by short-term, low-dose LPS activation via TLR4, has shown therapeutic promise but remains poorly characterized in CRC. We aimed to elucidate MSC1’s tumor-suppressive mechanisms and validate its activity against CRC cells using an integrated bioinformatics and in vitro approach. Methods: We constructed a high-confidence protein-protein interaction (PPI) network in Wharton’s jelly-derived MSCs (WJ-MSCs) following TLR4 activation to uncover enriched signaling pathways, transcriptional regulators, and secreted factors. Functional and transcriptional enrichment analyses pinpointed key mechanisms. We then co-cultured MSC1 cells with CRC cells to assess effects on proliferation and metabolism. Results: Network analysis revealed six tumor-suppressive mechanisms of MSC1 cells: (i) Metabolic reprogramming via enhanced glucose and lipid uptake, phosphoinositide signaling, and membrane/protein recycling, (ii) Robust antioxidant defenses, including SOS signaling and system xc⁻, (iii) Extracellular matrix stabilization and laminin-111–integrin-mediated adhesion, (iv) Secretome with direct anti-cancer effects, (v) Regulation of survival and cancer-associated fibroblasts (CAFs) formation inhibition through balanced proliferation, apoptosis, and epigenetic signals, (vi) Controlled pro-inflammatory signaling with anti-inflammatory feedback. In vitro, MSC1 cells significantly suppressed CRC cell proliferation and metabolic activity versus controls. Conclusions: This study provides the first mechanistic map of MSC1’s tumor-suppressive functions in CRC, extending beyond immunomodulation to include metabolic competition, ECM stabilization, and anti-cancer secretome activity. These findings establish MSC1 cells as a novel therapeutic strategy for CRC in cell-based cancer therapies.

28 June 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
DBDennis M. Bjorklund
Dennis M. Bjorklund
RMR. Marc L. Morgan
R. Marc L. Morgan
JOJasmeen Oberoi
Jasmeen Oberoi
KDKatie L. I. M. Day
Katie L. I. M. Day
PGPanagiota-Angeliki Galliou
Panagiota-Angeliki Galliou
Chrisostomos ProdromouChrisostomos Prodromou
Chrisostomos Prodromou
The kinome specific co-chaperone, CDC37 (cell division cycle 37), is responsible for delivering BRAF (B-Rapidly Accelerated Fibrosarcoma) to the Hsp90 (heat shock protein 90) complex, where it is then translocated to the RAS (protooncogene product p21) complex at the plasma membrane for RAS mediated dimerization and subsequent activation. We identify a bipartite interaction between CDC37 and BRAF and delimitate the essential structural elements of CDC37 involved in BRAF recognition. We find an extended and conserved CDC37 motif, 20HPNID---SL--W31, responsible for recognizing the C-lobe of BRAF kinase domain, while the c-terminal domain of CDC37 is responsible for the second of the bipartite interaction with BRAF. We show that dimerization of BRAF, independent of nucleotide binding, can act as a potent signal that prevents CDC37 recognition and discuss the implications of mutations in BRAF and the consequences on signaling in a clinical setting, particularly for class 2 BRAF mutations.

2 May 2019 in Journal of Biosciences
Verified
Journal Article
Closed access
PDF file
KVKleio-Maria Verrou
Kleio-Maria Verrou
PGPanagiota-Angeliki Galliou
Panagiota-Angeliki Galliou
MPMaria Papaioannou
Maria Papaioannou
Georgios KoliakosGeorgios Koliakos
Georgios Koliakos

20 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDennis M. Bjorklund
Dennis M. Bjorklund
RMR. Marc L. Morgan
R. Marc L. Morgan
JOJasmeen Oberoi
Jasmeen Oberoi
KDKatie L. I. M. Day
Katie L. I. M. Day
PGPanagiota-Angeliki Galliou
Panagiota-Angeliki Galliou
Chrisostomos ProdromouChrisostomos Prodromou
Chrisostomos Prodromou
The kinome specific co-chaperone, CDC37 (cell division cycle 37), is responsible for delivering BRAF (B-Rapidly Accelerated Fibrosarcoma) to the Hsp90 (heat shock protein 90) complex, where it is then translocated to the RAS (protooncogene product p21) complex at the plasma membrane for RAS mediated dimerization and subsequent activation. We identify a bipartite interaction between CDC37 and BRAF and delimitate the essential structural elements of CDC37 involved in BRAF recognition. We find an extended and conserved CDC37 motif, 20 HPNID---SL--W 31 , responsible for recognizing the C-lobe of BRAF kinase domain, while the c-terminal domain of CDC37 is responsible for the second of the bipartite interaction with BRAF. We show that dimerization of BRAF, independent of nucleotide binding, can act as a potent signal that prevents CDC37 recognition and discuss the implications of mutations in BRAF and the consequences on signaling in a clinical setting, particularly for class 2 BRAF mutations.

11 September 2024 in Journal of Biosciences
Verified
Journal Article
Closed access
PDF file
PGPanagiota-Angeliki Galliou
Panagiota-Angeliki Galliou
KVKleio-Maria Verrou
Kleio-Maria Verrou
NPNikolaos A Papanikolaou
Nikolaos A Papanikolaou
GKGeorge Koliakos
George Koliakos

1 June 2019 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
PGPanagiota-Angeliki Galliou
Panagiota-Angeliki Galliou
KVKleio-Maria Verrou
Kleio-Maria Verrou
Georgios KoliakosGeorgios Koliakos
Georgios Koliakos